Clinical efficacy of high-flux polysulfone dialyzer, FX-S

Clinical efficacy of high-flux polysulfone dialyzer, FX-S - Clinical efficacy of FX-S

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001275

Enrollment

Registered

2008-07-29

Start date

2008-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis

Interventions

Type 5 high-flux polysulfone (PS) dialyzer (FX-S) Type 4 PS dialyzer (FX)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All recruited patients underwent routine conventional bicarbonate HD three times a week (3 - 4 hours per session) using standard high-flux polysulfone (PS), and fully informed consent was obtained.

Exclusion criteria

Exclusion criteria: Patients with clinical signs of overt infection, acute vasculitis, or liver disease at the time of recruitment were excluded. So that lipid metabolism could be evaluated, patients taking lipid-lowering drugs such as statins, fibrates, ezetimibe, or ethyl icosapentate were also excluded from the study

Design outcomes

Primary

Measure	Time frame
At baseline, 3 months and 6 months, parameters of lipid, inflammation and oxidative stress	—

Secondary

Measure	Time frame
effectiveness for anemia and nutrition	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026